 MILAN, Italy and NEW YORK, Sept. 07, 2022 GLOBE NEWSWIRE -- Genenta Science NASDAQ: GNTA, a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several upcoming investor conferences in September and October. 